Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.56 USD
Change Today -0.16 / -4.30%
Volume 28.0K
OCRX On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 10:09 AM 04/28/15 All times are local (Market data is delayed by at least 15 minutes).

ocera therapeutics inc (OCRX) Snapshot

Open
$3.70
Previous Close
$3.72
Day High
$3.85
Day Low
$3.56
52 Week High
05/2/14 - $8.94
52 Week Low
04/28/15 - $3.56
Market Cap
70.3M
Average Volume 10 Days
140.6K
EPS TTM
$-1.42
Shares Outstanding
19.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OCERA THERAPEUTICS INC (OCRX)

Related News

No related news articles were found.

ocera therapeutics inc (OCRX) Related Businessweek News

No Related Businessweek News Found

ocera therapeutics inc (OCRX) Details

Ocera Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the development and commercialization of OCR-002, which is in Phase IIb trials for the treatment of hyperammonemia and hepatic encephalopathy in patients with liver cirrhosis, acute liver injury, and acute liver failure, as well as in the areas of unmet medical need. The company is headquartered in Palo Alto, California.

16 Employees
Last Reported Date: 03/13/15

ocera therapeutics inc (OCRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $198.8K
Compensation as of Fiscal Year 2013.

ocera therapeutics inc (OCRX) Key Developments

Jean-Paul Castaigne and Lars G. Ekman Not to Stand for Re-Election to Ocera Therapeutics Board of Directors

On April 23, 2015, each of Jean-Paul Castaigne, M.D. and Lars G. Ekman, M.D., Ph.D. informed the Board of Directors of Ocera Therapeutics, Inc. of their intention not to stand for re-election at the Company's 2015 Annual Meeting of Shareholders, and to retire from the Board effective as of the date of the Annual Meeting. Dr. Castaigne currently serves as a member of the Audit Committee and the Compensation Committee of the Board. The decisions by Dr. Castaigne and Dr. Ekman not to stand for reelection were not a result of any disagreement with the Company or the Board.

Ocera Therapeutics, Inc. Completes Interim Analysis of OCR-002 in Phase 2B STOP-HE study for the Treatment of Acute Hepatic Encephalopathy

Ocera Therapeutics, Inc. announced successful completion of a planned interim analysis of its STOP-HE study, a double-blind placebo-controlled study of OCR-002 in patients with acute hepatic encephalopathy (HE). The study's independent Data Monitoring Committee (DMC) reported that the trial is not futile and no drug-related safety signals have been observed in the study. Based on the DMC's recommendation, Ocera will continue the STOP-HE study and will increase target enrollment from 140 patients to approximately 230 patients. The Company remains blinded to data reviewed by the DMC in the interim analysis. HE is a serious, rare, progressive and episodic complication of liver cirrhosis, or liver failure, marked by mental changes including confusion, impaired motor skills, disorientation in time and space, and in its more severe form, stupor, coma and even death.

Ocera Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Cash Flow Guidance for the Year 2015

Ocera Therapeutics, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported loss from operations of $5,549,000 compared to $6,616,000 for the same period a year ago. Net loss from continuing operations was $5,538,000 or $0.28 per basic and diluted share compared to $6,606,000 or $0.48 per basic and diluted share for the same period a year ago. Net loss was $5,534,000 or $0.28 per basic and diluted share compared to $7,294,000 or $0.54 per basic and diluted share for the same period a year ago. Total revenue was $30,000 compared to $52,000 a year ago. For the year, the company reported loss from operations of $24,678,000 compared to $15,329,000 for the same period a year ago. Net loss from continuing operations was $24,624,000 or $1.41 per basic and diluted share compared to $15,486,000 or $2.52 per basic and diluted share for the same period a year ago. Net loss was $23,425,000 or $1.34 per basic and diluted share compared to $17,514,000 or $2.85 per basic and diluted share for the same period a year ago. Total revenue was $341,000 compared to $85,000 a year ago. The company expects net use of cash for 2015 to be between $28.0 million and $32.0 million. The company expects that it will have sufficient cash to fund operations to late 2016 based on its current operating plan.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OCRX:US $3.56 USD -0.16

OCRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OCRX.
View Industry Companies
 

Industry Analysis

OCRX

Industry Average

Valuation OCRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 225.2x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 86.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OCERA THERAPEUTICS INC, please visit www.ocerainc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.